An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Senseonics to Present at the Stifel 2022 Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Senseonics Holdings, Inc. (SENS), a leader in long-term implantable continuous glucose monitoring systems, has announced their participation in the Stifel Healthcare Conference in New York, NY. Scheduled for Tuesday, November 15, 2022, at 11:30am ET, management will engage in one-on-one meetings post-presentation. A live and recorded webcast will be accessible through a provided link.
Senseonics aims to enhance the lives of those with diabetes through its innovative glucose management technology, including the Eversense CGM system that continuously transmits glucose data to users' mobile devices.
Positive
None.
Negative
None.
GERMANTOWN, Md.--(BUSINESS WIRE)--
Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Stifel Healthcare Conference in New York, NY.
Management is scheduled to participate on Tuesday, November 15, 2022 at 11:30am ET and will hold one-on-one meetings following. Interested parties can access a live and recorded webcast presentation directly by following this link. An archived webcast of the presentation will be available on the “Investors” section of the company’s website at www.senseonics.com.
About Senseonics
Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems, Eversense®, Eversense® XL and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
Senseonics Investor Contact
Philip Taylor Investor Relations
415-937-5406
investors@senseonics.com
Source: Senseonics Holdings, Inc.
FAQ
When is Senseonics participating in the Stifel Healthcare Conference?
Senseonics will participate in the Stifel Healthcare Conference on Tuesday, November 15, 2022, at 11:30am ET.
Where can I access the webcast for Senseonics' conference presentation?
The webcast for Senseonics' conference presentation can be accessed through the provided link in their press release.
What is the focus of Senseonics' technology?
Senseonics focuses on developing long-term implantable continuous glucose monitoring systems for diabetes management.
What are the products offered by Senseonics?
Senseonics offers glucose monitoring products including the Eversense, Eversense XL, and Eversense E3 systems.
How does the Eversense CGM system work?
The Eversense CGM system includes a small sensor inserted under the skin that sends glucose data every 5 minutes to a smart transmitter and a mobile app.
